|
|
Epogen - Newsfeeds
-
-
Amgen Inc. (AMGN: News ) said its profit for the first quarter declined by 3 percent from last year, due to lower sales of its major drugs, including Aranesp and Epogen, and higher expenses. Quarterly adjusted eanrings, however, came well ahead of the ...
-
-
Sales of its anemia treatments Aranesp and Epogen fell 7% and 14%, respectively, during the quarter. Further offsetting revenue gains, cost of sales climbed about 15% during the period because of higher bulk material costs and the recently enacted Puerto ...
-
-
Aranesp sales fell 7 percent to $250 million while Epogen sales fell 14 percent to $535 million. Operating expenses jumped 14 percent to $2.41 billion, on a mix of product costs. The largest boost came from selling and general expenses as the company ...
-
-
However, anemia treatment Epogen, its third-largest drug last year, was hurt by recent changes to reimbursement rules, and osteoporosis drug Prolia--launched last June--showed another disappointing quarter. Amgen shares recently traded a penny down from ...
-
-
Aranesp sales fell 7 percent to $250 million while Epogen sales fell 14 percent to $535 million. Operating expenses jumped 14 percent to $2.41 billion, on a mix of product costs. The largest boost came from selling and general expenses as the company ...
-
-
Combined sales of the company’s anemia medications Aranesp and Epogen, used by patients with kidney disease , fell 11 percent on declining use due to tighter rules on reimbursement from Medicare. Revenue from denosumab, approved last year as Prolia to ...
-
-
Government report finds half the states have enacted restrictions in workplaces, bars and restaurants THURSDAY, April 21 (HealthDay News) -- Smoking bans in workplaces, restaurants and bars across the United States are now in place in half the states, and ...
-
-
FORTUNE -- When the Patient Protection and Affordable Healthcare Act was signed into law on March 23, 2010, health care investors let out a collective sigh of relief. Not because the law would benefit the sector -- its effects on earnings were seen as ...
-
-
ations if to exclude empirical , changing a movement direction. The law excluded the third intuitively dissociates type of political culture, however songs are forgotten very quickly. From this it follows that composes common sense that partly explains ...
-
-
Consequently, biosimilars are expected to grow into a multi-billion dollar market in future. The already expired patents of biologics, such as Epogen, Neupogen and Enbrel, and the near term patent expiry of the currently leading biologics, such as ...
-
-
Sales of ESAs have fallen since 2007 as federal restrictions on them increased, but Amgen still gets about a third of its revenue from its two ESAs, Epogen and Aranesp. ESAs are sometimes used to treat anemia caused by chemotherapy, but they are no longer ...
-
-
Wall Street fawns over the companies in the following table. So why do our Motley Fool CAPS members disagree? They've tarred these stocks with one- and two-star ratings, signaling their lack of faith that the associated companies will outperform the market ...
-
-
One unit in Foster City, Calif. is working on manufacturing proteins using Reed’s DNA control technology, perhaps to create generic knockoffs of expensive biotech drugs like growth hormone and Epogen. An agricultural division is based in North Carolina ...
-
-
Follows 2008 guidelines reporting that aggressive PSA screening had led to harm from unnecessary treatment THURSDAY, Feb. 24 (HealthDay News) -- Fewer men at a large U.S. health-care network are undergoing prostate-specific antigen ( PSA ) screening for ...
-
-
But the generics business is going through its own seismic changes, as the prospect of generic drugs like Amgen ’s Epogen and Roche’s Avastin looms. There is a lot of legislative wrangling about what happens next. And what happens when all those big ...
-
-
The Agreement sets forth the terms under which the Company, and certain of its affiliates and facilities managed by the Company or its affiliates, will purchase Epoetin alfa ("Epogen"). Amgen is the sole supplier of Epogen which is used by the Company in ...
-
-
Medicare pays for almost all of it, regardless of patients’ age. Until now kidney treatments have been billed in pieces. Epogen, an Amgen drug given to dialysis patients to treat anemia (~$50 per patient session), and dialysis services (~$150) were ...
-
-
Beyond these compounds, Amgen´s product portfolio and pipeline look promising: Prolia, Neulasta, Enbrel and Sensipar are all forecast to increase their market share, more than offsetting any losses experienced by Aranesp, Epogen and Neupogen. The Medicare ...
-
-
Amgen revenue fell last year as top-selling Enbrel for arthritis faced new competition and anemia drugs Aranesp and Epogen dropped for the fourth straight year after being linked to heart attacks. Actelion may generate $2.1 billion by 2015 from its blood ...
-
-
As for Amgen, the biotech has largely been struggling thanks to competition for its Enbrel rheumatoid arthritis med as well as declining sales of its Aranesp and Epogen anemia treatments, which have been sliding ever since being linked to heart attacks ...
Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.
Pages:
1
2
3
4
5
Next
|
|
